Inovio Pharmaceuticals (NASDAQ:INO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, January 9th.
According to Zacks, “Inovio’s progress with its lead pipeline candidate, VGX-3100, for treatment of cervical dysplasia is encouraging. We are also positive on the company’s collaboration with big pharma companies like Regeneron, AstraZeneca, and the University of Pennsylvania, as it lends Inovio with their expertise. Moreover, the company’s targeted cervical cancer market holds untapped potential. On the flip side, as the company has no approved product in its portfolio, its excessive dependence on its partners for funding the development of its pipeline candidates is concerning. Moreover, due to early/mid-stage nature of its pipeline, the candidates are several steps away from entering the market. Shares of the company have underperformed the industry in the last one year.”
INO has been the topic of several other reports. BidaskClub cut Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, October 27th. Citigroup began coverage on Inovio Pharmaceuticals in a report on Friday, October 6th. They set a “buy” rating and a $10.00 price target on the stock. HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 28th. Maxim Group reissued a “buy” rating and set a $12.00 price target on shares of Inovio Pharmaceuticals in a report on Tuesday, September 12th. Finally, Royal Bank of Canada started coverage on Inovio Pharmaceuticals in a report on Wednesday, October 18th. They issued an “outperform” rating and a $11.00 target price on the stock. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $19.16.
Shares of Inovio Pharmaceuticals (INO) opened at $4.25 on Tuesday. Inovio Pharmaceuticals has a 52 week low of $4.09 and a 52 week high of $9.86. The company has a market capitalization of $383.76, a price-to-earnings ratio of -3.60 and a beta of 2.54.
Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.15). The firm had revenue of $2.60 million for the quarter, compared to the consensus estimate of $10.27 million. Inovio Pharmaceuticals had a negative net margin of 221.55% and a negative return on equity of 72.19%. Inovio Pharmaceuticals’s quarterly revenue was down 79.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.28) earnings per share. analysts expect that Inovio Pharmaceuticals will post -1.12 EPS for the current year.
Large investors have recently bought and sold shares of the business. Wasatch Advisors Inc. raised its holdings in Inovio Pharmaceuticals by 43.6% during the second quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock valued at $20,469,000 after acquiring an additional 793,306 shares during the period. Allianz Asset Management GmbH raised its holdings in Inovio Pharmaceuticals by 12.4% during the third quarter. Allianz Asset Management GmbH now owns 222,768 shares of the biopharmaceutical company’s stock valued at $1,412,000 after acquiring an additional 24,652 shares during the period. OxFORD Asset Management LLP raised its holdings in Inovio Pharmaceuticals by 410.3% during the third quarter. OxFORD Asset Management LLP now owns 126,404 shares of the biopharmaceutical company’s stock valued at $799,000 after acquiring an additional 101,633 shares during the period. Vanguard Group Inc. raised its holdings in Inovio Pharmaceuticals by 4.2% during the second quarter. Vanguard Group Inc. now owns 3,227,219 shares of the biopharmaceutical company’s stock valued at $25,301,000 after acquiring an additional 129,164 shares during the period. Finally, First Interstate Bank raised its holdings in Inovio Pharmaceuticals by 291.9% during the third quarter. First Interstate Bank now owns 24,300 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 18,100 shares during the period. 32.12% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Inovio Pharmaceuticals (INO) Upgraded to Hold at Zacks Investment Research” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/05/inovio-pharmaceuticals-ino-lifted-to-hold-at-zacks-investment-research.html.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.